"uuid:ID","name","rationale","label","id","description","instanceType"
"4e1e313d-503a-4c4e-bad9-264daf5edc3b","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","","StudyDesign_1","The main design for the study","StudyDesign"
